Flufenoxine (F-98214-TA) is a Serotonin–norepinephrine reuptake inhibitor. It can be used to treat disorders of the central nervous system, particularly depression and anxiety. It was developed by a Spanish company at the beginning of the 21st century.[1]
Flufenoxine derivatives have been patented for the treatment of Alzheimer's disease.[2]
Analogues of Flufenoxine were reported containing a duloxetine-type thiophene surrogate ring moiety.[3] Such agents possess the desired triple-mode of activity (serotonin-noradrenaline and dopamine) (c.f. SNDRI).
For another related SNDRI agent see PC71812205. The racemic agent had IC50's of 11, 14, 190nM S~N>D.[4][5]
^Artaiz I, Zazpe A, Innerárity A, Del Olmo E, Díaz A, Ruiz-Ortega JA, et al. (November 2005). "Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties". Psychopharmacology. 182 (3): 400–13. doi:10.1007/s00213-005-0087-3. PMID16032410.
^Francisco Ledo Gómez, et al. WO2011147780 (Fabrica Espanola de Productos Quimicos y Farmaceuticos FAES SA).
^郭强, et al. WO2015131814 (to WUHAN JIAYU TECHNOLOGY Co Ltd, Nhwa Pharmaceutical Corp).
^Ishichi, Yuji; Kimura, Eiji; Honda, Eiji; Yoshikawa, Masato; Nakahata, Takashi; Terao, Yasuko; Suzuki, Atsuko; Kawai, Takayuki; Arakawa, Yuuichi; Ohta, Hiroyuki; Kanzaki, Naoyuki; Nak-agawa, Hideyuki; Terauchi, Jun (2013). "Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds". Bioorganic & Medicinal Chemistry. 21 (15): 4600–4613. doi:10.1016/j.bmc.2013.05.025.
